Modeling anxiety in healthy humans: a key intermediate bridge between basic and clinical sciences

Article metrics

Abstract

Animal models of anxiety disorders are important for elucidating neurobiological defense mechanisms. However, animal models are limited when it comes to understanding the more complex processes of anxiety that are unique to humans (e.g., worry) and to screen new treatments. In this review, we outline how the Experimental Psychopathology approach, based on experimental models of anxiety in healthy subjects, can mitigate these limitations and complement research in animals. Experimental psychopathology can bridge basic research in animals and clinical studies, as well as guide and constrain hypotheses about the nature of psychopathology, treatment mechanisms, and treatment targets. This review begins with a brief review of the strengths and limitations of animal models before discussing the need for human models of anxiety, which are especially necessary to probe higher-order cognitive processes. This can be accomplished by combining anxiety-induction procedures with tasks that probe clinically relevant processes to identify neurocircuits that are potentially altered by anxiety. The review then discusses the validity of experimental psychopathology and introduces a methodological approach consisting of five steps: (1) select anxiety-relevant cognitive or behavioral operations and associated tasks, (2) identify the underlying neurocircuits supporting these operations in healthy controls, 3) examine the impact of experimental anxiety on the targeted operations in healthy controls, (4) utilize findings from step 3 to generate hypotheses about neurocircuit dysfunction in anxious patients, and 5) evaluate treatment mechanisms and screen novel treatments. This is followed by two concrete illustrations of this approach and suggestions for future studies.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Stein MB, Craske MG. Treating Anxiety in 2017: optimizing care to improve outcomes. JAMA 2017;318:E1–E2.

  2. 2.

    Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617–27.

  3. 3.

    Chisholm D, Sweeny K, Sheehan P, Rasmussen B, Smit F, Cuijpers P, et al. Scaling-up treatment of depression and anxiety: a global return on investment analysis. Lancet Psychiatry 2016;3:415–24.

  4. 4.

    LeDoux JE, Pine DS. Using neuroscience to help understand fear and anxiety: a two-system framework. Am J Psychiatry 2016;173:1083–93.

  5. 5.

    Koen N, Stein DJ. Pharmacotherapy of anxiety disorders: a critical review. Dialog Clin Neurosci 2011;13:423–37.

  6. 6.

    Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. Nat Neurosci 2010;13:1161–9.

  7. 7.

    Zoellner LA, Foa EB. Applying Research Domain Criteria (RDoC) to the study of fear and anxiety: a critical comment. Psychophysiol 2016;53:332–5.

  8. 8.

    Nutt D, Goodwin G. ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin. Eur Neuropsychopharmacol 2011;21:495–9.

  9. 9.

    Grillon C, Chavis C, Covington MS, Pine DS. Two-week treatment with citalopram reduces contextual anxiety but not cued fear. Neuropsychopharmacol 2009;34:964–71.

  10. 10.

    Grillon C, Baas JMP, Pine DS, Lissek S, Lawley M, Ellis V, et al. The benzodiazepine alprazolam dissociates contextual fear from cued fear in humans as assessed by fear-potentiated startle. Biol Psychiatry 2006;60:760–6.

  11. 11.

    American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th edn. Washingron, DC: American Psychiatric Association; 2013.

  12. 12.

    Davis M, Walker DL, Miles L, Grillon C. Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs. anxiety. Neuropsychopharmacol 2010;35:105–35.

  13. 13.

    Barlow DH. Anxiety and its disorders: the nature and treatment of anxiety and panic. New York: Guilford Press; 1988.

  14. 14.

    Mineka S, Zinbarg R. Conditioning and ethological models of anxiety disorders: stress-in-dynamic-context anxiety models. In: Hope DA, editor. Perspective on Anxiety, Panic, & Fear. Lincoln and London: University of Nebraska Press; 1996. pp. 135–210.

  15. 15.

    Schmitz A, Grillon C. Assessing fear and anxiety in humans using threat of predictable and unpredictable aversive events (the NPU-threat test). Nat Protoc 2012;7:527–32.

  16. 16.

    Kirschbaum C, Pirke KM, Hellhammer DH. The ‘Trier Social Stress Test’–a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 1993;28:76–81.

  17. 17.

    Dedovic K, Renwick R, Mahani NK, Engert V, Lupien SJ, Pruessner JC. The Montreal Imaging Stress Task: using functional imaging to investigate the effects of perceiving and processing psychosocial stress in the human brain. J Psychiatry Neurosci 2005;30:318–25.

  18. 18.

    Kogler L, Müller VI, Chang A, Eickhoff SB, Fox PT, Gur RC, et al. Psychosocial versus physiological stress—meta-analyses on deactivations and activations of the neural correlates of stress reactions. NeuroImage 2015;119:235–51.

  19. 19.

    Blumenthal TD, Chapman JG, Muse KB. Effects of social anxiety, attention, and extraversion on the acoustic startle eyeblink response. Personal Individ Differ 1995;19:797–807.

  20. 20.

    Vytal K, Cornwell B, Arkin N, Grillon C. Describing the interplay between anxiety and cognition: from impaired performance under low cognitive load to reduced anxiety under high load. Psychophysiology 2012;49:842–52.

  21. 21.

    Robinson OJ, Bond RL, Roisier JP. The impact of threat of shock on the framing effect and temporal discounting: executive functions unperturbed by acute stress? Front Psychol 2015;6:1315.

  22. 22.

    Gillan CM, Vaghi MM, Hezemans FH, van Ghesel GS, Dafflon J, Brühl AB, et al. Experimentally-induced and real-world acute anxiety have no effect on goal-directed behaviour. bioRxiv. 2019:606145.

  23. 23.

    Bailey JE, Papadopoulos A, Lingford-Hughes A, Nutt DJ. D-Cycloserine and performance under different states of anxiety in healthy volunteers. Psychopharmacology 2007;193:579–85.

  24. 24.

    Garner M, Attwood A, Baldwin DS, James A, Munafò MR. Inhalation of 7.5% carbon dioxide increases threat processing in humans. Neuropsychopharmacol 2011;36:1557–62.

  25. 25.

    Garner M, Attwood A, Baldwin D, Munafò M. Inhalation of 7.5% carbon dioxide increases alerting and orienting attention network function. Psychopharmacology 2012;223:67–73.

  26. 26.

    Rollin MDH, Rollin BE. Crazy like a fox: validity and ethics of animal models of human psychiatric disease. Camb Q Health Ethics 2014;23:140–51.

  27. 27.

    Kaiser T, Feng G. Modeling psychiatric disorders for developing effective treatments. Nat Med 2015;21:979.

  28. 28.

    Santos M, D’Amico D, Dierssen M. From neural to genetic substrates of panic disorder: insights from human and mouse studies. Eur J Pharmacol. 2015;759:127–41.

  29. 29.

    Bueters T, Ploeger BA, Visser SAG. The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives. Drug Discov Today 2013;18:853–62.

  30. 30.

    Dawson GR, Goodwin G. Experimental medicine in psychiatry. J Psychopharmacol 2005;19:565–6.

  31. 31.

    Griebel G, Holmes A. 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov 2013;12:667–87.

  32. 32.

    Rodgers RJ. Animal models of ‘anxiety’: where next? Behav Pharmacol 1997;8:477–96.

  33. 33.

    MacLean EL. Unraveling the evolution of uniquely human cognition. Proc Natl Acad Sci USA 2016;113:6348–54.

  34. 34.

    Pringle A, Harmer CJ. The effects of drugs on human models of emotional processing: an account of antidepressant drug treatment. Dialog- Clin Neurosci 2015;17:477–87.

  35. 35.

    Grillon C, Hale E, Lieberman L, Davis A, Pine DS, Ernst M. The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle. Neuropsychopharmacol 2015;40:1064–71.

  36. 36.

    Bailey J, Papadopoulos A, Diaper A, Phillips S, Schmidt M, van der Ark P, et al. Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the7.5% CO(2) proof-of-concept experimental model of human anxiety. J Psychopharmacol 2011;25:1199–206.

  37. 37.

    Pine DS. Clinical advances from a computational approach to anxiety. Biol Psychiatry 2017;82:385–7.

  38. 38.

    Montoya A, Bruins R, Katzman MA, Blier P. The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatr Dis Treat 2016;12:541–57.

  39. 39.

    Harmer CJ, Cowen PJ ‘It’s the way that you look at it’—a cognitive neuropsychological account of SSRI action in depression. Philos Trans R Soc B. 2013;368:20120407. https://doi.org/10.1098/rstb.2012.0407.

  40. 40.

    Balderston NL, Roberts C, Masi E, Deng Z-D, Radman T, Luber B, et al. A causal link between right dlPFC Activity and anxiety expression revealed using repetitive transcranial magnetic stimulation. in 2019 Annual meeting of the Society of Biological Psychiatry, Chicago, 2019.

  41. 41.

    Pine DS, Helfinstein SM, Bar Haim Y, Nelson E, Fox NA. Challenges in developing novel treatments for childhood disorders: lessons from research on anxiety. Neuropsychopharmacol 2008;34:213–28.

  42. 42.

    Forsyth JP, Zvolensky MJ. Experimental psychopathology, clinical science, and practice: an irrelevant or indispensable alliance? Appl Prev Psychol 2001;10:243–64.

  43. 43.

    Vervliet B, Raes F. Criteria of validity in experimental psychopathology: application to models of anxiety and depression. Psychol Med 2012;43:2241–4.

  44. 44.

    Kotov R, Krueger RF, Watson D, Achenbach TM, Althoff RR, Bagby RM, et al. The Hierarchical Taxonomy of Psychopathology (HiTOP): a dimensional alternative to traditional nosologies. J Abnorm Psychol 2017;126:454–77.

  45. 45.

    Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiat 2010;167:748–51.

  46. 46.

    Bjelland I, Lie SA, Dahl AA, Mykletun A, Stordal E, Kraemer HC. A dimensional versus a categorical approach to diagnosis: Anxiety and depression in the HUNT 2 study. Int J Methods Psychiatr Res. 2009;18:128–37.

  47. 47.

    Watson D, Gamez W, Simms LJ. Basic dimensions of temperament and their relation to anxiety and depression: a symptom-based perspective. J Res Pers 2005;39:46–66.

  48. 48.

    Calhoon GG, Tye KM. Resolving the neural circuits of anxiety. Nat Neurosci 2015;18:1394–404.

  49. 49.

    Robinson OJ, Krimsky M, Grillon C. The impact of induced anxiety on response inhibition. Front Hum Neurosci 2013;7:69.

  50. 50.

    Costello CG. Two dimensional views of psychopathology. Behav Res Ther 1994;32:391–402.

  51. 51.

    Greco JA, Liberzon I. Neuroimaging of fear-associated learning. Neuropsychopharmacology 2016;41:320–34.

  52. 52.

    Benkelfat C, Bradwejn J, Meyer E, Ellenbogen M, Milot S, Gjedde A, et al. Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers. Am J Psychiatry 1995;152:1180–4.

  53. 53.

    Eser D, Leicht G, Lutz J, Wenninger S, Kirsch V, Schule C, et al. Functional neuroanatomy of CCK-4-induced panic attacks in healthy volunteers. Hum Brain Mapp 2009;30:511–22.

  54. 54.

    Bailey JE, Dawson GR, Dourish CT, Nutt DJ. Validating the inhalation of 7.5% CO2 in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD). J Psychopharmacol 2011;25:1192–8.

  55. 55.

    Roberson-Nay R, Gorlin EI, Beadel JR, Cash T, Vrana S, Teachman BA. Temporal stability of multiple response systems to 7.5% carbon dioxide challenge. Biol Psychol 2017;124:111–8.

  56. 56.

    Papadopoulos A, Rich A, Nutt D, Bailey J. The effects of single dose anxiolytic medication on the CO2 models of anxiety: differentiation of subjective and objective measures. J Psychopharmacol 2010;24:649–56.

  57. 57.

    Bailey JE, Papadopoulos A, Seddon K, Nutt DJ. A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO2 models of experimental human anxiety. J Psychopharmacol 2008;23:117–22.

  58. 58.

    Bailey JE, Argyropoulos SV, Kendrick AH, Nutt DJ. Behavioral and cardiovascular effects of 7.5% CO2 in human volunteers. Depress Anxiety 2005;21:18–25.

  59. 59.

    Bailey JE, Kendrick A, Diaper A, Potokar J, Nutt DJ. A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers. J Psychopharmacol 2007;21:42–49.

  60. 60.

    Grillon C, Pellowski M, Merikangas KR, Davis M. Darkness facilitates the acoustic startle in humans. Biol Psychiatry 1997;42:453–60.

  61. 61.

    Grillon C, Morgan CA, Davis M, Southwick SM. Effect of darkness on acoustic startle in Vietnam veterans with PTSD. Am J Psychiatry 1998;155:812–7.

  62. 62.

    Kamkwalala A, Norrholm SD, Poole JM, Brown A, Donley S, Duncan E, et al. Dark-enhanced startle responses and heart rate variability in a traumatized civilian sample: putative sex-specific correlates of posttraumatic stress disorder. Psychosom Med 2012;74:153–9.

  63. 63.

    Grillon C, Ameli R, Woods SW, Merikangas K, Davis M. Fear-potentiated startle in humans: effects of anticipatory anxiety on the acoustic blink reflex. Psychophysiology 1991;28:588–95.

  64. 64.

    Shankman SA, Robison-Andrew EJ, Nelson BD, Altman SE, Campbell ML. Effects of predictability of shock timing and intensity on aversive responses. Int J Psychophysiol 2011;80:112–8.

  65. 65.

    Seddon K, Morris K, Bailey J, Potokar J, Rich A, Wilson S, et al. Effects of 7.5% CO2 challenge in generalized anxiety disorder. J Psychopharmacol 2011;25:43–51.

  66. 66.

    Grillon C, Pine DS, Lissek S, Rabin S, Bonne O, Vythilingam M. Increased anxiety during anticipation of unpredictable aversive stimuli in posttraumatic stress disorder but not in generalized anxiety disorder. Biol Psychiatry 2009;66:47–53.

  67. 67.

    Grillon C, Lissek S, Rabin S, McDowell D, Dvir S, Pine DS. Increased anxiety during anticipation of unpredictable but not predictable aversive stimuli as a psychophysiologic marker of panic disorder. Am J Psychiatry 2008;165:898–904.

  68. 68.

    Gorka S, Liu H, Sarapas C, Shankman S. Time course of threat responding in panic disorder and depression. Int J Psychophysiol 2015;98:87–94.

  69. 69.

    Gorka SM, Nelson BD, Shankman SA. Startle response to unpredictable threat in comorbid panic disorder and alcohol dependence. Drug Alcohol Depend 2013;132:216–22.

  70. 70.

    Gorka SM, Hee D, Lieberman L, Mittal VA, Phan KL, Shankman SA. Reactivity to uncertain threat as a familial vulnerability factor for alcohol use disorder. Psychol Med 2016;46:1–10.

  71. 71.

    Gorka SM, Lieberman L, Phan KL, Shankman SA. Startle potentiation to uncertain threat as a psychophysiological indicator of fear-based psychopathology: an examination across multiple internalizing disorders. J Abnorm Psychol. 2017;126:8–18.

  72. 72.

    Moberg CA, Bradford DE, Kaye JT, Curtin JJ. Increased startle potentiation to unpredictable stressors in alcohol dependence: possible stress neuroadaptation in humans. J Abnorm Psychol 2017;126:441–53.

  73. 73.

    Figel B, Brinkmann L, Buff C, Heitmann CY, Hofmann D, Bruchmann M, et al. Phasic amygdala and BNST activation during the anticipation of temporally unpredictable social observation in social anxiety disorder patients. NeuroImage: Clin 2019;22:101735.

  74. 74.

    Buff C, Brinkmann L, Bruchmann M, Becker MPI, Tupak S, Herrmann MJ, et al. Activity alterations in the bed nucleus of the stria terminalis and amygdala during threat anticipation in generalized anxiety disorder. Soc Cogn Affect Neurosci 2017;12:1766–74.

  75. 75.

    Brinkmann L, Buff C, Neumeister P, Tupak SV, Becker MPI, Herrmann MJ, et al. Dissociation between amygdala and bed nucleus of the stria terminalis during threat anticipation in female post-traumatic stress disorder patients. Hum Brain Mapp 2017;38:2190–205.

  76. 76.

    Brinkmann L, Buff C, Feldker K, Tupak SV, Becker MPI, Herrmann MJ, et al. Distinct phasic and sustained brain responses and connectivity of amygdala and bed nucleus of the stria terminalis during threat anticipation in panic disorder. Psychol Med 2017;47:1–14.

  77. 77.

    Herrmann MJ, Boehme S, Becker MPI, Tupak SV, Guhn A, Schmidt B, et al. Phasic and sustained brain responses in the amygdala and the bed nucleus of the stria terminalis during threat anticipation. Hum Brain Mapp 2016;37:1091–102.

  78. 78.

    Alvarez R, Lissek S, Biggs A, Grillon C. Contextual fear conditioning in a virtual reality environment: a fMRI study. in The Organization for Human Brain Mapping, Chicago, Il 2007.

  79. 79.

    Alvarez RP, Biggs A, Chen G, Pine DS, Grillon C. Contextual fear conditioning in humans: cortical-hippocampal and amygdala contributions. J Neurosci 2008;28:6211–9.

  80. 80.

    Alvarez RP, Chen G, Bodurka J, Kaplan R, Grillon C. Phasic and sustained fear in humans elicits distinct patterns of brain activity. Neuroimage 2011;1:389–400.

  81. 81.

    McMenamin BW, Langeslag SJE, Sirbu M, Padmala S, Pessoa L. Network organization unfolds over time during periods of anxious anticipation. J Neurosci 2014;34:11261–73.

  82. 82.

    McMenamin BW, Pessoa L. Discovering networks altered by potential threat (“anxiety”) using quadratic discriminant analysis. NeuroImage 2015;116:1–9.

  83. 83.

    Bijsterbosch J, Smith S, Bishop SJ. Functional connectivity under anticipation of shock: correlates of trait anxious affect versus induced anxiety. J Cogn Neurosci 2015;27:1–14.

  84. 84.

    Pessoa L. A network model of the emotional brain. Trends Cogn Sci 2017;21:357–71.

  85. 85.

    Baars BJ, Franklin S. How conscious experience and working memory interact. Trends Cogn Sci 2003;7:166–72.

  86. 86.

    Mathews A, Mackintosh BA. A cognitive model of selective processing in anxiety. Cogn Ther Res 1998;22:539–60.

  87. 87.

    Eysenck MW, Derakshan N, Santos R, Calvo MG. Anxiety and cognitive performance: attentional control theory. Emotion 2007;7:336–53.

  88. 88.

    Kopp CB. Antecedents of self-regulation: a developmental perspective. Dev Psychol 1982;18:199–214.

  89. 89.

    Hofmann W, Schmeichel BJ, Baddeley AD. Executive functions and self-regulation. Trends Cogn Sci 2012;16:174–80.

  90. 90.

    Hartley CA, Phelps EA. Anxiety and decision-making. Biol Psychiatry 2012;72:113–8.

  91. 91.

    Derryberry D, Reed MA. Anxiety-related attentional biases and their regulation by attentional control. J Abnorm Psychol 2002;111:225–36.

  92. 92.

    Bar-Haim Y, Lamy D, Pergamin L, Bakermans-Kranenburg MJ, van IMH. Threat-related attentional bias in anxious and nonanxious individuals: a meta-analytic study. Psychol Bull 2007;133:1–24.

  93. 93.

    Bishop SJ. Trait anxiety and impoverished prefrontal control of attention. Nat Neurosci 2009;12:92–98.

  94. 94.

    Walters E, Carew T, Kandel E. Associative Learning in Aplysia: evidence for conditioned fear in an invertebrate. Science 1981;211:504–6.

  95. 95.

    Davis M. The role of the amygdala in fear-potentiated startle: implication for animal models of anxiety. Trends Pharmacol Sci 1992;13:35–41.

  96. 96.

    Kuhn M, Wendt J, Sjouwerman R, Büchel C, Hamm A, Lonsdorf TB. The neurofunctional basis of affective startle modulation in humans—evidence from combined facial EMG-fMRI. bioRxiv. 2019:567032.

  97. 97.

    Beck AT, Clark DA. An information processing model of anxiety: automatic and strategic processes. Behav Res Ther 1997;35:49–58.

  98. 98.

    Robinson OJ, Lieberman L, Allen P, Vytal K, Grillon C. The dorsal medial prefrontal-amygdala ‘aversive amplification’ circuit in unmedicated generalized and social anxiety disorders. Lancet Psychiatry 2014;1:294–302.

  99. 99.

    Borkovec TD, Alcaine OM, Behar E. Avoidance theory of worry and generalized anxiety disorder. In: Heimberg RG, Turk CL, Mennin DS, editors. Generalized anxiety disorder: advances in research and practice. New York: Guilford; 2004. pp. 77–108.

  100. 100.

    Morris LW, Liebert RM. Effects of negative feedback, threat of shock, and level of trait anxiety on the arousal of two components of anxiety. J Couns Psychol 1973;20:321–6.

  101. 101.

    Mennin DS, Heimberg RG, Turk CL, Fresco DM. Applying an emotion regulation framework to integrative approaches to generalized anxiety disorder. Clin Psychol: Sci Pract 2002;9:85–90.

  102. 102.

    Kagan J, Reznick JS, Snidman N. Biological basis of childhood shyness. Science 1988;240:167–71.

  103. 103.

    Dymond S. Overcoming avoidance in anxiety disorders: the contributions of Pavlovian and operant avoidance extinction methods. Neurosci Biobehav Rev. 2019;98:61–70.

  104. 104.

    Cornwell BR, Garrido MI, Overstreet C, Pine DS, Grillon C. The un-predictive brain under threat: a neuro-computational account of anxious hypervigilance. Biol Psychiatry 2017;82:447–54.

  105. 105.

    Cornwell BR, Baas JMP, Johnson L, Holroyd T, Carver FW, Lissek S, et al. Neural responses to auditory stimulus deviance under threat of electric shock revealed by spatially-filtered magnetoencephalography. Neuroimage 2007;37:282–9.

  106. 106.

    Weinberg A, Klein DN, Hajcak G. Increased error-related brain activity distinguishes generalized anxiety disorder with and without comorbid major depressive disorder. J Abnorm Psychol 2012;121:885–96.

  107. 107.

    Criteria NAMHCWoTaMfRD: Behavioral Assessment Methods for RDoC Constructs. in A Report by the National Advisory Mental Health Council Workgroup on Tasks and Measures for Research Domain Criteria (RDoC), Bethesda, MD, Z:/PDF_3/Anxiety-disorders/RDoC; 2016. pp. pp. 163.

  108. 108.

    Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004;56:301–7.

  109. 109.

    Brovelli A, Ding M, Ledberg A, Chen Y, Nakamura R, Bressler SL. Beta oscillations in a large-scale sensorimotor cortical network: directional influences revealed by Granger causality. Proc Natl Acad Sci USA 2004;101:9849–54.

  110. 110.

    Friston KJ, Harrison L, Penny W. Dynamic causal modelling. NeuroImage 2003;19:1273–302.

  111. 111.

    Friston K, Moran R, Seth AK. Analysing connectivity with Granger causality and dynamic causal modelling. Curr Opin Neurobiol 2013;23:172–8.

  112. 112.

    Robinson OJ, Chase HW. Learning and choice in mood disorders: searching for the computational parameters of anhedonia. Comput Psychiatr 2017;1:208–33.

  113. 113.

    Charpentier CJ, Hindocha C, Roiser JP, Robinson OJ. Anxiety promotes memory for mood-congruent faces but does not alter loss aversion. Sci Rep 2016;6:24746.

  114. 114.

    Sussman TJ, Szekely A, Hajcak G, Mohanty A. It’s all in the anticipation: how perception of threat is enhanced in anxiety. Emotion 2016;16:320–7.

  115. 115.

    Weymar M, Bradley MM, Hamm AO, Lang PJ. Encoding and reinstatement of threat: recognition potentials. Neurobiol Learn Mem 2014;107:87–92.

  116. 116.

    Yang Y, Miskovich TA, Larson CL. State pnxiety impairs proactive but enhances reactive control. Front Psychol 2018;9:2570.

  117. 117.

    Clarke RJ, Johnstone T. Prefrontal inhibition of threat processing reduces working memory interference. Front Hum Neurosci. 2013;7:228. https://doi.org/10.3389/fnhum.2013.00228.

  118. 118.

    Pessoa L, Padmala S, Kenzer A, Bauer A. Interactions between cognition and emotion during response inhibition. Emotion 2012;12:192–7.

  119. 119.

    Choi J, Padmala S, Pessoa L. Impact of state anxiety on the interaction between threat monitoring and cognition. Neuroimage 2012;59:1912–23.

  120. 120.

    Robinson OJ, Vytal K, Cornwell BR, Grillon C. The impact of anxiety upon cognition: perspectives from human threat of shock studies. Front Hum Neurosci 2013;7:203.

  121. 121.

    Cooper R, Howard CJ, Attwood AS, Stirland R, Rostant V, Renton L, et al. Acutely induced anxiety increases negative interpretations of events in a closed-circuit television monitoring task. Cogn Emot 2013;27:273–82.

  122. 122.

    Shin LM, Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology. 2010;35:169–191. https://doi.org/10.1038/npp.2009.83.

  123. 123.

    Forster GL, Simons RL, Baugh LA: Revisiting the role of the amygdala in posttraumatic stress disorder. In: B. Ferry editor. The amygdala: Where emotions shape perception, learning and memories. London: InTech; 2017. pp. 113–36. https://doi.org/10.5772/67585.

  124. 124.

    Lang PJ, McTeague LM, Bradley MMRDoC. DSM, and the reflex physiology of fear: a biodimensional analysis of the anxiety disorders spectrum. Psychophysiology 2016;53:336–47.

  125. 125.

    Bradford DE, Shapiro BL, Curtin JJ. How bad could It be? Alcohol dampens stress responses to threat of uncertain intensity. Psychol Sci 2013;24:2541–9.

  126. 126.

    Pringle A, Warren M, Gottwald J, Cowen PJ, Harmer CJ. Cognitive mechanisms of diazepam administration: a healthy volunteer model of emotional processing. Psychopharmacology 2016;233:2221–8.

  127. 127.

    Murphy SE, Yiend J, Lester KJ, Cowen PJ, Harmer CJ. Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers. Int J Neuropsychopharmacol 2009;12:169–79.

  128. 128.

    Valdez GR. Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date. CNS Drugs 2006;20:887–96.

  129. 129.

    Risbrough VB, Stein MB. Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Horm Behav 2006;50:550–61.

  130. 130.

    Walker D, Yang Y, Ratti E, Corsi M, Trist D, Davis M. Differential effects of the CRF-R1 antagonist GSK876008 on fear-potentiated, light- and CRF-enhanced startle suggest preferential involvement in sustained vs phasic threat responses. Neuropsychopharmacol 2009;34:1533–42.

  131. 131.

    Griebel G, Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat Rev Drug Discov 2012;11:462–78.

  132. 132.

    Schwandt ML, Cortes CR, Kwako LE, George DT, Momenan R, Sinha R, et al. The CRF1 antagonist verucerfont in anxious alcohol-dependent women: translation of neuroendocrine, but not of anti-craving effects. Neuropsychopharmacology 2016;41:2818–29.

  133. 133.

    Dunlop BW, Binder EB, Iosifescu D, Mathew SJ, Neylan TC, Pape JC, et al. Corticotropin-releasing factor type 1 receptor antagonism is ineffective for women with posttraumatic stress disorder. Biol Psychiatry 2017;82:866–74.

  134. 134.

    Lago TR, Hsiung A, Leitner BP, Duckworth CJ, Balderston NL, Chen KY, et al. Exercise modulates the interaction between cognition and anxiety in humans. Cogn Emot. 2019;33:863–70. https://doi.org/10.1080/02699931.2018.1500445.

  135. 135.

    Gorka SM, Lieberman L, Klumpp H, Kinney KL, Kennedy AE, Ajilore O, et al. Reactivity to unpredictable threat as a treatment target for fear-based anxiety disorders. Psychol Med 2017;47:1–11.

  136. 136.

    Costello CG. Anxiety and the persisting novelty of input from the autonomic nervous system. Behav Ther 1971;2:321–33.

  137. 137.

    Gray JA. The psychology of fear and stress. Cambridge: Cambridge University Press; 1987.

  138. 138.

    Ludewig S, Geyer MA, Ramseier M, Vollenweider FX, Rechsteiner E, Cattapan-Ludewig K. Information-processing deficits and cognitive dysfunction in panic disorder. J Psychiatry Neurosci 2005;30:37–43.

  139. 139.

    Ludewig S, Ludewig K, Geyer MA, Hell D, Vollenweider FX. Prepulse inhibition deficits in patients with panic disorder. Depress Anxiety 2002;15:55–60.

  140. 140.

    Morgan CA III, Grillon C. Abnormal mismatch negativity in women with sexual assault-related posttraumatic stress disorder. Biol Psychiatry 1999;45:827–32.

  141. 141.

    Ge Y, Wu J, Sun X, Zhang K. Enhanced mismatch negativity in adolescents with posttraumatic stress disorder (PTSD). Int J Psychophysiol 2011;79:231–5.

  142. 142.

    Chang Y, Xu J, Pang X, Sun Y, Zheng Y, Liu Y. Mismatch negativity indices of enhanced preattentive automatic processing in panic disorder as measured by a multi-feature paradigm. Biol Psychol 2015;105:77–82.

  143. 143.

    Wessel JR, Aron AR. On the globality of motor suppression: unexpected events and their influence on behavior and cognition. Neuron 2017;93:259–80.

  144. 144.

    Näätänen R, Kujala T, Winkler I. Auditory processing that leads to conscious perception: a unique window to central auditory processing opened by the mismatch negativity and related responses. Psychophysiology 2011;48:4–22.

  145. 145.

    Näätänen R, Paavilainen P, Titinen H, Jiang D, Alho K. Attention and mismatch negativity. Psychophysiology 1993;30:436–50.

  146. 146.

    Fan L, Sun Y-B, Sun Z-K, Wang N, Luo F, Yu F, et al. Modulation of auditory sensory memory by chronic clinical pain and acute experimental pain: a mismatch negativity study. Sci Rep 2018;8:15673.

  147. 147.

    Gené-Cos N, Ring HA, Pottinger RC, Barrett G. Possible roles for mismatch negativity in neuropsychiatry. Cogn Behav Neurol 1999;12:17–27.

  148. 148.

    Mager R, Bullinger AH, Mueller-Spahn F, Kuntze MF, Stoermer R. Real-time monitoring of brain activityin patients with specific phobia during exposure therapy, employing a stereoscopi virtual environment. Cyber Behav 2001;4:465–9.

  149. 149.

    Marshall PJ, Reeb BC, Fox NA. Electrophysiological responses to auditory novelty in temperamentally different 9-month-old infants. Dev Sci 2009;12:568–82.

  150. 150.

    Giard MH, Perrin F, Pernier J, Bouchet P. Brain generators implicated in the processing of auditory stimulus deviance: a topographic event-related potential study. Psychophysiology 1990;27:6627–40.

  151. 151.

    Garrido MI, Kilner JM, Stephan KE, Friston KJ. The mismatch negativity: a review of underlying mechanisms. Clin Neurophysiol 2009;120:453–63.

  152. 152.

    Davis M. The role of the amygdala in fear and anxiety. Annu Rev Neurosci 1992;15:353–75.

  153. 153.

    Vuilleumier P. How brains beware: neural mechanisms of emotional attention. Trends Cogn Sci 2005;9:585–94.

  154. 154.

    Wessel JR, Danielmeier C, Morton JB, Ullsperger M. Surprise and error: common neuronal architecture for the processing of errors and novelty. J Neurosci 2012;32:7528–37.

  155. 155.

    Ousdal OT, Andreassen OA, Server A, Jensen J. Increased amygdala and visual cortex activity and functional connectivity towards stimulus novelty is associated with state anxiety. PLoS ONE 2014;9:e96146.

  156. 156.

    D’Hulst C, Atack JR, Kooy RF. The complexity of the GABAA receptor shapes unique pharmacological profiles. Drug Discov Today. 2009;14:866–75.

  157. 157.

    Pellow S, File SE. Multiple sites of action for anxiogenic drugs: behavioural, electrophysiological and biochemical correlations. Psychopharmacol 1984;83:304–15.

  158. 158.

    Smolnik R, Pietrowsky R, Fehm HL, Born J. Enhanced selective attention after low-dose administration of the benzodiazepine antagonist flumazenil. J Clin Psychopharmacol 1998;18:241–7.

  159. 159.

    Nakagome K, Ichikawa I, Kanno O, Akaho R, Suzuki M, Takazawa S, et al. Overnight effects of triazolam on cognitive function: an event-related potentials study. Neuropsychobiology 1998;38:232–40.

  160. 160.

    Rosburg T, Marinou V, Haueisen J, Smesny S, Sauer H. Effects of lorazepam on the neuromagnetic mismatch negativity (MMNm) and auditory evoked field component N100m. Neuropsychopharmacology 2004;29:1723–33.

  161. 161.

    Grillon C, Charney DR. In the face of fear: anxiety sensitizes defensive responses to fearful faces. Psychophysiology 2011;12:1745–52.

  162. 162.

    Morris JS, DeGelder B, Weiskrantz L, Dolan RJ. Differential extrageniculostriate and amygdala responses to presentation of emotional faces in a cortically blind field. Brain 2001;124:1241–52.

  163. 163.

    Whalen PJ, Rauch SL, Etcoff NL, McInerney SC, Lee MB, Jenike MA. Masked presentations of emotional facial expressions modulate amygdala activity without explicit knowledge. J Neurosci 1998;18:411–8.

  164. 164.

    Bishop S, Duncan J, Brett M, Lawrence AD. Prefrontal cortical function and anxiety: controlling attention to threat-related stimuli. Nat Neurosci 2004;7:184–8.

  165. 165.

    Dolcos F, McCarthy G. Brain systems mediating cognitive interference by emotional distraction. J Neurosci 2006;26:2072–9.

  166. 166.

    MacDonald AW, Cohen JD, Stenger VA, Carter CS. Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. Science 2000;288:1835–8.

  167. 167.

    Robinson OJ, Letkiewicz AM, Overstreet C, Ernst M, Grillon C. The effect of induced anxiety on cognition: threat of shock enhances aversive processing in healthy individuals. Cogn Affect Behav Neurosci 2011;11:217–27.

  168. 168.

    Robinson OJ, Charney DR, Overstreet C, Vytal K, Grillon C. The adaptive threat bias in anxiety: amygdala-dorsomedial prefrontal cortex coupling and aversive amplification. Neuroimage 2012;60:523–9.

  169. 169.

    Etkin A, Egner T, Kalisch R. Emotional processing in anterior cingulate and medial prefrontal cortex. Trends Cogn Sci 2011;15:85–93.

  170. 170.

    Vytal K, Overstreet C, Charney D, Robinson OJ, Grillon C. Sustained anxiety increases amygdala-dorsomedial prefrontal coupling: a mechanism for maintaining an anxious state. J Psychiatry Neurosci 2014;39:321–9.

  171. 171.

    Robinson OJ, Krimsky M, Lieberman L, Vytal K, Ernst M, Grillon C. Anxiety-potentiated amygdala-medial frontal coupling and attentional control. Transl Psychiatry 2016;6:e833.

  172. 172.

    Robinson OJ, Cools R, Crockett MJ, Sahakian BJ. Mood state moderates the role of serotonin in cognitive biases. J Psychopharmacol 2010;24:573–83.

  173. 173.

    Harmer CJ. Serotonin and emotional processing: does it help explain antidepressant drug action? Neuropharmacology 2008;55:1023–8.

  174. 174.

    Nutt DJ. The neuropharmacology of serotonin and noradrenaline in depression. Int Clin Psychopharmacol 2002;17 (Suppl. 1):S1–S12.

  175. 175.

    Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002;297:400–3.

  176. 176.

    Robinson OJ, Overstreet C, Allen PS, Letkiewicz A, Vytal K, Pine DS, et al. The role of serotonin in the neurocircuitry of negative affective bias: serotonergic modulation of the dorsal medial prefrontal-amygdala ‘aversive amplification’ circuit. Neuroimage 2013;78:217–23.

  177. 177.

    Walsh AEL, Harmer CJ. The cognitive neuropsychological model of antidepressant response. Curr Opin Psychol 2015;4:124–30.

  178. 178.

    Butler AC, Chapman JE, Forman EM, Beck AT. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev. 2006;26:17–31.

  179. 179.

    McLean CP, Asnaani A, Litz BT, Hofmann SG. Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. J Psychiatr Res 2011;45:1027–35.

  180. 180.

    Patel N, Vytal K, Pavletic N, Stoodley C, Pine DS, Grillon C, et al. Interaction of threat and verbal working-memory in adolescents. Psychophysiology 2016;53:518–26.

  181. 181.

    Lieberman LC, Gorka SM, Sarapas C, Shankman SA. Cognitive flexibility mediates the relation between intolerance of uncertainty and safety signal responding in those with panic disorder. Cogn Emot 2015;30:1495–503.

  182. 182.

    Gorka SM, Lieberman L, Nelson BD, Sarapas C, Shankman SA. Aversive responding to safety signals in panic disorder: the moderating role of intolerance of uncertainty. J Anxiety Disord 2014;28:731–6.

  183. 183.

    Roberson-Nay R, Beadel JR, Gorlin EI, Latendresse SJ, Teachman BA. Examining the latent class structure of CO2 hypersensitivity using time course trajectories of panic response systems. J Behav Ther Exp Psychiatry 2015;47:68–76.

  184. 184.

    Nay WT, Thorpe GL, Roberson-Nay R, Hecker JE, Sigmon ST. Attentional bias to threat and emotional response to biological challenge. J Anxiety Disord 2004;18:609–27.

  185. 185.

    Kane MJ, Engle RW. The role of prefrontal cortex in working-memory capacity, executive attention, and general fluid intelligence: An individual-differences perspective. Psychon Bull Rev. 2002;9:637–71.

  186. 186.

    Insel TR. Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Arch Gen Psychiatry 2009;66:128–33.

  187. 187.

    Blanchard RJ, Blanchard DC. Anti-predator defense as models of fear and anxiety. In: Brain PF, Blanchard RJ, Parmigiani S, editors. Fear and Defense. Amsterdam, Netherlands: Harwood Academic Publishers; 1990. pp. 89–108.

  188. 188.

    Blanchard RJ, McKittrick CR, Blanchard DC. Animal models of social stress: effects on behavior and brain neurochemical systems. Physiol Behav. 2001;73:261–71.

  189. 189.

    Kogler L, Müller VI, Chang A, Eickhoff SB, Fox PT, Gur RC, et al. Psychosocial versus physiological stress—meta-analyses on deactivations and activations of the neural correlates of stress reactions. NeuroImage 2015;119:235–51.

  190. 190.

    Kaye JT, Bradford DE, Curtin JJ. Psychometric properties of startle and corrugator response in NPU, affective picture viewing, and resting state tasks. Psychophysiology 2016;53:1241–55.

  191. 191.

    Baldwin DS, Hou R, Gordon R, Huneke NTM, Garner M. Pharmacotherapy in generalized anxiety disorder: novel experimental medicine nodels and emerging drug targets. CNS Drugs 2017;31:307–17.

  192. 192.

    Price M, Anderson PL. Latent growth curve analysis of fear during a speech task before and after treatment for social phobia. Behav Res Ther 2011;49:763–70.

  193. 193.

    Goldin PR, Manber T, Hakimi S, Canli T, Gross JJ. Neural bases of social anxiety disorder: emotional reactivity and cognitive regulation during social and physical threat. Arch Gen Psychiatry 2009;66:170–80.

  194. 194.

    Biedermann SV, Biedermann DG, Wenzlaff F, Kurjak T, Nouri S, Auer MK, et al. An elevated plus-maze in mixed reality for studying human anxiety-related behavior. BMC Biol 2017;15:125–125.

  195. 195.

    Iordan AD, Dolcos S, Dolcos F. Brain activity and network interactions in the impact of internal emotional distraction. Cereb Cortex 2018;29:1–17.

  196. 196.

    Balderston NL, Liu L, Roberson-Nay R, Ernst M, Grillon C. The relationship between dlPFC activity during unpredictable threat and CO2-induced panic symptoms. Transl Psychiatry 2017;7:1266.

Download references

Author information

Correspondence to Christian Grillon.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Grillon, C., Robinson, O.J., Cornwell, B. et al. Modeling anxiety in healthy humans: a key intermediate bridge between basic and clinical sciences. Neuropsychopharmacol. 44, 1999–2010 (2019) doi:10.1038/s41386-019-0445-1

Download citation

Further reading